Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
AstraZeneca's TRUQAP showed significant progress in treating aggressive prostate cancer, with better survival rates.
AstraZeneca's new treatment, TRUQAP, combined with abiraterone and androgen deprivation therapy, significantly improved progression-free survival in patients with a specific type of aggressive prostate cancer compared to standard treatment.
The treatment showed promising early results in overall survival and had a consistent safety profile.
The data will be presented at an upcoming medical meeting and shared with regulators.
5 months ago
3 Articles